IMR Press / FBS / Volume 4 / Issue 2 / DOI: 10.2741/s282

Frontiers in Bioscience-Scholar (FBS) is published by IMR Press from Volume 13 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


CARs: Driving T-cell specificity to enhance anti-tumor immunity

Show Less
1 Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas
2 Division of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, Texas

*Author to whom correspondence should be addressed.

Academic Editor:Edmund K. Waller

Front. Biosci. (Schol Ed) 2012, 4(2), 520–531;
Published: 1 January 2012
(This article belongs to the Special Issue New insights in immunology)

Adoptive transfer of antigen-specific T cells is a compelling tool to treat cancer. To overcome issues of immune tolerance which limits the endogenous adaptive immune response to tumor-associated antigens, robust systems for the genetic modification and characterization of T cells expressing chimeric antigen receptors (CARs) to redirect specificity have been produced. Refinements with regards to persistence and trafficking of the genetically modified T cells are underway to help improve the potency of genetically modified T cells. Clinical trials utilizing this technology demonstrate feasibility, and increasingly, antitumor activity, paving the way for multi-center trials to establish the efficacy of this novel T-cell therapy.

Chimeric antigen receptor
T cell therapy
Cellular Therapy
Cancer Therapeutics
Lymphoid Malignancies
Back to top